A study of 18F-FLT positron emission tomography/computed tomography imaging in cases of prefibrotic/early primary myelofibrosis and essential thrombocythemia

Abstract

The objectives of this research project are to study in patients with primary myelofibrosis (PMF) and Essential Thrombocythemia (ET); (1) the uptake patterns of 18 FLT-PET (FLT-PET) and its value in diagnosing, staging, and treatment response monitoring of malignant hematopoiesis, (2) compare imaging findings from FLT-PET with bone marrow biopsy (standard of care), and (3) associate FLT-PET uptake patterns with genetic makeup such as JAK2 (Janus kinase 2), CALR (Calreticulin), MPL (myeloproliferative leukemia protein), Triple negative disease, and allele burden. This trial is registered in ClinicalTrials.gov with number NCT03116542. Protocol version: Mar 2017

Assessing Bone Marrow Activity with [18F]FLT PET in Patients with Essential Thrombocythemia and Prefibrotic Myelofibrosis: A Proof of Concept

“…The objective of this study is to explore the diagnostic value of FLT-PET in malignant hematopoiesis of Pre-PMF and ET. The potential to use FLT-PET metrics to differentiate between Pre-PMF and ET is assessed 3 since this differentiation will optimize the therapeutic interventions (eg, anti-platelets and anti-coagulants) as thrombosis is related to ET while hemorrhage is more associated with pre-PMF.…”

Coexistence of Prefibrotic Myelofibrosis with Monoclonal Gammopathy of Undetermined Significance: A Case Report

“…It has heterogeneous clinical presentation that varies from isolated thrombocytosis, similar to ET, up to symptoms of high-risk PMF. Retrospective studies showed that survival of patients with pre-PMF is worse than that of ET and better than overt PMF [ 4 ].…”

Myasthenia Gravis and Myeloproliferative Neoplasms – Mere Association or Paraneoplastic Neurologic Syndrome: A Mini-Review

“…MG is a recognized paraneoplastic syndrome in patients with thymoma (~15% of MG patients) [7], secondary to AChR/MuSK antibodies' production from the thymic source. Only 31% had thymoma in our cohort, whereas 77% had positive AChR/ MuSK antibodies.…”

“…2016 WHO category of MPNs includes the three major subcategories of Janus kinase 2 (JAK2)/ calreticulin (CALR)/ myeloproliferative leukemia virus oncogene (MPL) mutation-related MPNs: Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Primary Myelofibrosis (PMF), as well as four other clinic-pathologic entities: chronic myeloid leukemia (CML), chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia, not otherwise specified (CEL-NOS) and MPN, unclassifiable (MPN-U) [6]. PMF includes pre-fibrotic/early PMF (pre-PMF) as well [7]. The diagnostic hallmark of CML is the invariable presence of the BCR-ABL1 mutation [6,8,9].…”